Part,  Chapter, Paragraph

 1   II,     5.  2.  5|           resolutions and charters (EUR/RC56/R2; WHA53.17; EUR/RC52/
 2   II,     5.  2.  5|              EUR/RC56/R2; WHA53.17; EUR/RC52/R12; EUR/RC55/R1; EUR/
 3   II,     5.  2.  5|             WHA53.17; EUR/RC52/R12; EUR/RC55/R1; EUR/RC54/R3; EUR/
 4   II,     5.  2.  5|          EUR/RC52/R12; EUR/RC55/R1; EUR/RC54/R3; EUR/RC55/R6) have
 5   II,     5.  2.  5|           EUR/RC55/R1; EUR/RC54/R3; EUR/RC55/R6) have been adopted
 6   II,     5.  2.  7|          from the EUROCISS Project. Eur J Public Health 13: 55-60~
 7   II,     5.  2.  7|        practice: executive summary. Eur Heart J 28: 2375-414~Greenland
 8   II,     5.  2.  7|        Union between 1970 and 2000. Eur Heart J 27: 107-113.~Kuulasmaa
 9   II,     5.  2.  7|            from the Progetto CUORE. Eur J Cardiovasc Prev Rehabil
10   II,     5.  2.  7|     morbidity statistics in Europe. Eur Heart J 18: 1231–48.~Sarti
11   II,     5.  3.  9|           cancer health indicators. Eur J Public Health 13(3 Suppl):
12   II,     5.  5.  1|           Sweden from 1997 to 2005. Eur Psychiatry 22(3):146-52.~ ~S G (
13   II,     5.  5.  3|             of the brain in Europe. Eur J Neurol 12 Suppl 1:1-27.~
14   II,     5.  5.  3|      psychotic disorders in Europe. Eur J Neurol 12 Suppl 1:74-77.~
15   II,     5.  5.  3|       psychosis: facts and visions. Eur Arch Psychiatry Clin Neurosci
16   II,     5.  5.  3|          between research and care. Eur Arch Psychiatry Clin Neurosci
17   II,     5.  5.  3|       Europe – a systematic review. Eur J Neurol 12:245-253.~Fraser
18   II,     5.  5.  3|           Csongrád County, Hungary. Eur Neurol 46:206-209.~Benedikz
19   II,     5.  5.  3|    incidence over a 25-year period. Eur J Neurol 8:463-469.~Confavreux
20   II,     5.  5.  3|              trends, and prospects. Eur J Neurol 11:511–520~EUROPA.
21   II,     5.  5.  3|         Multiple Sclerosis Society. Eur Neurol. 2006;56(2):78-105~
22   II,     5.  5.  3|          province of Evros, Greece. Eur Neurol 49:8-12.~Poser CM,
23   II,     5.  5.  3|       multiple sclerosis in Europe. Eur J Neurol 13: 700722.~Pugliatti
24   II,     5.  5.  3|             of the brain in Europe. Eur J Neurol 12 Suppl 1:1-27.~
25   II,     5.  5.  3| uncomplicated) Parkinson’s disease. Eur J Neurol 13(11):1170-1185.~
26   II,     5.  5.  3|      Parkinson’s disease in Europe. Eur J Neurol 12 Suppl 1:68-73.~
27   II,     5.  5.  3|      Parkinson’s disease in Europe. Eur Neuropsychopharmacol 15(
28   II,     5.  6.  6|      symptoms in a local community. Eur J Gen Pract 1:25-28~Naz
29   II,     5.  7.  7|             the general population. Eur Heart J 2006 May;27(10):
30   II,     5.  8.  7|           exposed to inorganic dust~Eur Respir J 23: 402-406.~ ~
31   II,     5.  8.  7|       Chronic Respiratory Diseases.~Eur Respir J 2007; 29: 233-239.~ ~
32   II,     5.  8.  7|             ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.~ ~
33   II,     5.  8.  7|             phlegm in young adults. Eur Respir J 2003; 22: 413-417.~ ~
34   II,     5.  8.  7|      obstructive pulmonary disease. Eur Respir J 2006; 27: 188-207.~ ~
35   II,     5.  8.  7|           review and meta-analysis. Eur Respir J 2006; 28: 523-532.~ ~
36   II,     5.  8.  7|     multiple cause coding analysis. Eur Respir J 2003; 22: 809-814.~ ~
37   II,     5.  8.  7|            research in Europe: FP7. Eur Respir J 2007; 29: 223-225.~ ~
38   II,     5.  8.  7|              what's the difference? Eur J Public Health 2006; 16:
39   II,     5.  8.  7|         sample: the NICECOPD study. Eur J Epidemiol 2005; 20: 443-
40   II,     5.  8.  7|          disease”. Siafakas NM eds. Eur Respir Mon, Monograph 38,
41   II,     5.  8.  7|            natural history of COPD. Eur Respir J 2007; 30: 993–1013~ ~
42   II,     5.  8.  7|            with smoking cigarettes. Eur J Epidemiol 2004; 19: 147-
43   II,     5.  8.  7|          Increasing COPD awareness. Eur Respir J 2006; 27: 833-852.~ ~
44   II,     5.  9.  7|         1996): The costs of asthma. Eur Respir J. 2006 Apr;9(4):
45   II,     5.  9.  7|          Respiratory Health Survey. Eur Respir J, 1994, 7, 954-960~ ~
46   II,     5.  9.  7|       Survey-II Steering Committee. Eur Respir J 2002; 20:1071-1079~ ~
47   II,     5.  9.  7|        predictors: the RHINE study. Eur Respir J 2004; 24: 942-946~ ~To E,
48   II,     5. 10.  7|          gluten in coeliac disease. Eur J Gastroenterol Hepatol
49   II,     5. 10.  7|           symptoms in young adults. Eur Respir J 1998; 11(1):151-
50   II,     5. 10.  7|           Survey (ECRHS) 1991-1994. Eur J Clin Nutr 2001; 55(4):
51   II,     5. 10.  7|           allergy in the community. Eur J Clin Nutr; 56(1):31-36.~ ~
52   II,     5. 11.  3|             skin diseases in Europe Eur J Dermatol 2006;16:212-218~ ~ ~
53   II,     5. 11.  7|           from a European survey. J Eur Acad Dermatol Venereol 2005;
54   II,     5. 11.  7|            review. Onychomycosis. J Eur Acad Dermatol Venereol.
55   II,     5. 11.  7|         Vaud: an update, 19761998. Eur J Cancer Prev 2001;10:371–
56   II,     5. 11.  7|             skin diseases in Europe Eur J Dermatol 2006:16:212-218.~ ~ ~ ~
57   II,     7.  5    |             implementing resolution EUR/RC55/R9 during the past
58   II,     7.  7    |            the WHO European Region. EUR/RC55/R9 of September 15,
59   II,     8.  2.  1|             A European perspective. Eur J Public Health 13: 47-50;
60   II,     9.  1.  1|          health outcomes in Europe. Eur J Obstet Gynecol Reprod
61   II,     9.  1.  1|       hospitals: descriptive study. Eur J Obstet Gynecol Reprod
62   II,     9.  1.  1|          Medical Experts Committee. Eur J Obstet Gynecol Reprod
63   II,     9.  1.  1|  childbearing population in Europe. Eur J Obstet Gynecol Reprod
64   II,     9.  1.  1|           study in The Netherlands. Eur J Obstet Gynecol Reprod
65   II,     9.  1.  1|              a retrospective study. Eur J Obstet Gynecol Reprod
66   II,     9.  1.  1|          from the PERISTAT project. Eur J Obstet Gynecol Reprod
67   II,     9.  1.  2|  chlidbearing population in Europe. Eur J Obstet Gynecol Repr Biol,
68   II,     9.  2.  7|     mortality in Europe, 19551995. Eur J Cancer. 37:785-809.~ ~
69   II,     9.  3.  1|         Randomized Controlled Trial Eur Urol 51: 659-664~ ~Austbury
70   II,     9.  3.  2|          health outcomes in Europe. Eur J Obstet Gynecol Reprod
71   II,     9.  3.  2|       hospitals: descriptive study. Eur J Obstet Gynecol Reprod
72   II,     9.  3.  2|          Medical Experts Committee. Eur J Obstet Gynecol Reprod
73   II,     9.  3.  2|  childbearing population in Europe. Eur J Obstet Gynecol Reprod
74   II,     9.  3.  2|           study in The Netherlands. Eur J Obstet Gynecol Reprod
75   II,     9.  3.  2|              a retrospective study. Eur J Obstet Gynecol Reprod
76   II,     9.  3.  2|          The Netherlands 1983-1992. Eur J Obstet Gynecol Reprod
77   II,     9.  3.  2|              The REPROSTAT project. Eur J Obstet Gynecol Reprod
78   II,     9.  3.  2|          from the PERISTAT project. Eur J Obstet Gynecol Reprod
79   II,     9.  3.  3|     countries: a systematic review. Eur J Public Health. 0: ckm014v1-7~
80   II,     9.  3.  3|         health education campaigns. Eur J Public Health 16(5):498-
81  III,    10.  2.  1|          Respiratory Health Survey. Eur Respir J 2006; 27:517-524~ ~
82  III,    10.  2.  1|             cohort study 1984-1992. Eur Heart J, 1998; 19: 1997-
83  III,    10.  2.  1|              PEP) (ECE/AC.21/2002/9-EUR/02/5040828/9)-Geneva [htt ~ ~
84  III,    10.  2.  1|             INN-CA Study 1994-1996. Eur. J. Clin. Nutr. 55 (7),
85  III,    10.  2.  1|           Geneva, (ECE/AC.21/2002/9-EUR/02/5040828/9): (http://www.
86  III,    10.  2.  1|          consumption survey method. Eur J Clin Nutr 56 Suppl 2:
87  III,    10.  3.  1|           an overall cost of around EUR 4 billion (Boegli, 2006).~ ~
88  III,    10.  3.  1|           mortality in Europe 1995. Eur. J. Cancer 38, 99-166.~Darby
89  III,    10.  4.  3|            and International Lakes. EUR/ICP/EHCO 020205/8Fin, 18
90   IV,    12.  2    |           resolutions and charters (EUR/RC56/R2; WHA53.17; EUR/RC52/
91   IV,    12.  2    |              EUR/RC56/R2; WHA53.17; EUR/RC52/R12; EUR/RC55/R1; EUR/
92   IV,    12.  2    |             WHA53.17; EUR/RC52/R12; EUR/RC55/R1; EUR/RC54/R3; EUR/
93   IV,    12.  2    |          EUR/RC52/R12; EUR/RC55/R1; EUR/RC54/R3; EUR/RC55/R6) have
94   IV,    12.  2    |           EUR/RC55/R1; EUR/RC54/R3; EUR/RC55/R6) have been adopted
95   IV,    13.  7.  3|         themes. The “Healththeme (EUR 6.0 billion) currently covers
96   IV,    13.  7.  3|              the largest in FP7with EUR 9.1 billion - supports the
97   IV,    13.  7.  3|            and biotechnology theme (EUR 1.9 billion), the food,
98   IV,    13.  7.  3|        While the ERC is funded with EUR 7.5 billion over 7 years,
99   IV,    13.  9    |             of the brain in Europe. Eur J Neurol 12 Suppl 1:1-27.~